Vanda Pharmaceuticals Inc.

Form 4

August 15, 2007

### FORM 4

#### UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF

**SECURITIES** 

**OMB APPROVAL OMB** 

Number:

3235-0287

Expires:

January 31, 2005

0.5

Estimated average

response...

burden hours per

if no longer subject to Section 16. Form 4 or Form 5

Check this box

obligations may continue. See Instruction

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section

30(h) of the Investment Company Act of 1940

1(b).

(Print or Type Responses)

1. Name and Address of Reporting Person ** Polymeropoulos Mihael Hristos				2. Issuer Name <b>and</b> Ticker or Trading Symbol			5. Relationship of Reporting Person(s) to Issuer			
			Vanda Pharmaceuticals Inc. [VNDA]			(Check all applicable)				
	(Last)	(First)	(Middle)	3. Date o	of Earliest T	ransaction				
9605 MEDICAL CENTER DRIVE, SUITE 300				(Month/I 08/13/2	Day/Year) 2007		X Director 10% OwnerX Officer (give title Other (specify below) Chief Executive Officer			
(Street)			4. If Amendment, Date Original			6. Individual or Joint/Group Filing(Check				
				Filed(Month/Day/Year)			Applicable Line) _X_ Form filed by One Reporting Person			
ROCKVILLE, MD 20850						Form filed by M Person	ore than One Re	porting		
	(City)	(State)	(Zip)	Table I - Non-Derivative Securities Acq			quired, Disposed of, or Beneficially Owned			
	1.Title of Security	2. Transaction Day (Month/Day/Year			3. Transactio	4. Securities Acquired (Approx Disposed of (D)	5. Amount of Securities	6. Ownership	7. Nature of Indirect	

						_	<del>-</del>		=
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transactic Code (Instr. 8)	4. Securit or Dispos (Instr. 3, 4	ed of (4 and 5 (A) or	5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code V	Amount	(D)	Price	(Instr. 5 und 1)		
Common Stock	08/13/2007(1)		M	10,000	A	\$ 0.0331	10,000	D	
Common Stock	08/13/2007(1)		S	10,000	D	\$ 16.23	0	D	

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of SEC 1474 information contained in this form are not (9-02)required to respond unless the form displays a currently valid OMB control number.

#### Edgar Filing: Vanda Pharmaceuticals Inc. - Form 4

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactic Code (Instr. 8)	5. Number proof Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	ative Expiration Date es (Month/Day/Year) d		7. Title and Amount of Underlying Securities (Instr. 3 and 4)	
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (Right to Buy)	\$ 0.331	08/13/2007(1)		M	2,675	<u>(2)</u>	02/10/2015	Common Stock	2,675
Employee Stock Option (Right to Buy)	\$ 0.331	08/13/2007(1)		M	7,325	(2)	09/28/2015	Common Stock	7,325

## **Reporting Owners**

Reporting Owner Name / Address	Relationships					
	Director	10% Owner	Officer	Othe		
Polymeropoulos Mihael Hristos 9605 MEDICAL CENTER DRIVE SUITE 300 ROCKVILLE, MD 20850	X		Chief Executive Officer			

#### **Signatures**

/s/ Mihael H.
Polymeropoulos

\*\*Signature of Reporting Person Date

# **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Transaction was administered pursuant to an authorized 10b5-1 plan.
- (2) Exercisable with respect to 25% of the shares one year after the grant, exercisable with respect to an additional 2.08333% of the aggregate shares each month thereafter.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Reporting Owners 2

# Edgar Filing: Vanda Pharmaceuticals Inc. - Form 4

tential persons who are to respond to the collection of information contained in this form are not required to respond unless the urrently valid OMB number.	form displays